Recruiting
Phase 3
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
This is a single-dose, open-label study in pediatric participants with severe SCD and hydroxyurea (HU) failure or intolerance. The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (CTX001).
ClinicalTrials.gov Identifier
Eligibility criteria
Sex
Age
2 Years - 11 Years
Phase
3
Key inclusion criteria
- Diagnosis of severe SCD as defined by:
- Documented SCD genotypes
- History of at least two severe VOCs events per year for the previous two years prior to enrollment
- Hydroxyurea (HU) failure unless HU intolerant
- Eligible for autologous stem cell transplant as per investigators judgment
Key exclusion criteria
- A willing and healthy 10/10 human leukocyte antigen (HLA)-matched related donor
- Prior hematopoietic stem cell transplant (HSCT).
- Clinically significant and active bacterial, viral, fungal, or parasitic infection
Other protocol defined Inclusion/Exclusion criteria may apply.
Trial details
Condition
Sickle Cell Disease, Hydroxyurea Failure, Hydroxyurea Intolerance, Hemoglobinopathies, Hematological Diseases
Study duration
May 2022 - May 2026
Study type
Interventional
Intervention/Treatment
Biological : CTX001
Estimated enrollment
15
Interested in this trial?
About clinical trials
Volunteers who participate in clinical trials help make new medicines a reality. Clinical trials are carefully designed research studies in humans that evaluate the safety and efficacy of an investigational medicine.
If you’re interested in participating in a Vertex clinical trial, we encourage you to speak with your health care provider first about what’s involved and your eligibility.
Location
x
-
Recruiting1Children's Hospital of PhiladelphiaPhiladelphia Pennsylvania 19104 United States
-
Recruiting1St. Jude Children's Research HospitalMemphis Tennessee 38105 United States
-
Recruiting1The Children's Hospital at TriStar Centennial Medical Center/ Sarah Cannon Center for Blood CancersNashville Tennessee 37203 United States